A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal—results 6–18 months after implantation into New Zealand white rabbits

OBJECTIVE To determine whether corrodible materials may be safely used as biodegradable cardiovascular implants. DESIGN Corrodible iron stents (> 99.8% iron) were produced from pure iron and laser cut with a stent design similar to a commercially available permanent stent (PUVA-AS16). A total of 16 NOR-I stents were implanted into the native descending aorta of 16 New Zealand white rabbits (mean luminal diameter at the implantation site 3.4 mm, balloon diameter to vessel diameter ratio 1.13). RESULTS No thromboembolic complications and no adverse events occurred during the follow up of 6–18 months. All stents were patent at repeat angiography after 6 (n = 9), 12 (n = 5), and 18 months (n = 2) with no significant neointimal proliferation, no pronounced inflammatory response, and no systemic toxicity. CONCLUSIONS This initial in vivo experience suggests that degradable iron stents can be safely implanted without significant obstruction of the stented vessel caused by inflammation, neointimal proliferation, or thrombotic events.

[1]  J. Suárez de Lezo,et al.  Immediate and follow-up findings after stent treatment for severe coarctation of aorta. , 1999, The American journal of cardiology.

[2]  S. Ho,et al.  Transcatheter stent implantation to treat aortic coarctation in infancy. , 1993, British heart journal.

[3]  E. Topol,et al.  Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. , 1996, Circulation.

[4]  J. Lock,et al.  Implantation and Intermediate‐Term Follow‐up of Stents in Congenital Heart Disease , 1993, Circulation.

[5]  Keiji Igaki,et al.  A Biodegradable Poly‐l‐lactic Acid Coronary Stent in the Porcine Coronary Artery , 1999 .

[6]  J. Winchester,et al.  A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  B. McCrindle,et al.  Endovascular stents in the pulmonary circulation. Clinical impact on management and medium-term follow-up. , 1995, Circulation.

[8]  H. Brauer,et al.  Biophysikalische Prüfung koronarer Stents: Welche Faktoren beeinflussen das Dilatations- und Recoilverhalten? , 2000, Zeitschrift für Kardiologie.

[9]  R. Beekman,et al.  Intraoperative and Percutaneous Stenting of Congenital Pulmonary Artery and Vein Stenosis , 1993, Circulation.

[10]  J. Palmaz,et al.  Re-expansion of balloon-expandable stents after growth. , 1993, Journal of the American College of Cardiology.

[11]  P. Chatelain,et al.  Stenting of superior vena cava and inferior vena cava for symptomatic narrowing after repeated atrial surgery for D-transposition of the great vessels. , 1991, British heart journal.

[12]  J. Lock,et al.  Use of Endovascular Stents in Congenital Heart Disease , 1991, Circulation.

[13]  L. Latson,et al.  Use of balloon-expandable stents for coarctation of the aorta: initial results and intermediate-term follow-up. , 1997, Journal of the American College of Cardiology.

[14]  L. Benson,et al.  Endovascular stents in pediatric cardiovascular medicine. , 1995, Journal of interventional cardiology.

[15]  S. Qureshi,et al.  Stent implantation for aortic recoarctation. , 1995, American heart journal.

[16]  R. Lerner,et al.  Clinical use of the total dose intravenous infusion of iron dextran. , 1988, The Journal of laboratory and clinical medicine.

[17]  S. Qureshi,et al.  Stent implantation for aortic coarctation and recoarctation , 1999, Heart.

[18]  H. Uehata,et al.  Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. , 2000, Circulation.

[19]  A. Garson,et al.  Pediatric therapeutic cardiac catheterization: a statement for healthcare professionals from the Council on Cardiovascular Disease in the Young, American Heart Association. , 1998, Circulation.

[20]  E J Topol,et al.  Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. , 1997, Journal of the American College of Cardiology.

[21]  W. J. van der Giessen,et al.  Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. , 1998, Journal of the American College of Cardiology.

[22]  M. O'Laughlin,et al.  Intravascular stents in congenital heart disease: short- and long-term results from a large single-center experience. , 1998, Journal of the American College of Cardiology.

[23]  C. Mullins,et al.  Use of intravascular stents in systemic venous and systemic venous baffle obstructions. Short-term follow-up results. , 1995, Circulation.

[24]  C. Mullins,et al.  783-5 Intravascular Stents in Systemic Venous and Systemic Venous Baffle Obstructions , 1995 .

[25]  A. Colombo,et al.  Biodegradable stents : "fulfilling the mission and stepping away". , 2000, Circulation.

[26]  M. Leon,et al.  Chronic arterial responses to stent implantation: a serial intravascular ultrasound analysis of Palmaz-Schatz stents in native coronary arteries. , 1996, Journal of the American College of Cardiology.

[27]  B. Thanopoulos,et al.  Stent treatment for coarctation of the aorta: intermediate term follow up and technical considerations , 2000, Heart.

[28]  J. Suárez de Lezo,et al.  Balloon-expandable stent repair of severe coarctation of aorta. , 1995, American heart journal.

[29]  M. Rabinowitch,et al.  Percutaneous implantation of a balloon-expandable endoprosthesis for pulmonary artery stenosis: an experimental study. , 1991, Journal of the American College of Cardiology.

[30]  C. Mullins,et al.  Repeat dilation of intravascular stents in congenital heart defects. , 1995, Circulation.

[31]  N. Andrews,et al.  Disorders of iron metabolism. , 1999, The New England journal of medicine.

[32]  H Shimokawa,et al.  Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. , 1998, Journal of the American College of Cardiology.

[33]  A. Redington,et al.  Self expanding stents in congenital heart disease. , 1994, British heart journal.